In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y

Ann Intern Med. 2016 Oct 18;165(8):JC38. doi: 10.7326/ACPJC-2016-165-8-038.
No abstract available

Publication types

  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2*
  • Glycated Hemoglobin
  • Humans
  • Hypoglycemic Agents
  • Liraglutide*
  • Risk
  • Treatment Outcome

Substances

  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Liraglutide